Results 61 to 70 of about 3,886 (197)

Industry Perspective on Current Guidelines, Challenges, and Future Directions for ADME Characterization of Payloads for Antibody‐Drug Conjugates

Pharmacology Research &Perspectives, Volume 14, Issue 6, December 2026.
ABSTRACT A total of 15 antibody‐drug conjugates (ADC)s have been approved by USFDA till December 2025 with the use of nine cytotoxic payload molecules. Small molecule payloads can undergo enzymatic or nonenzymatic biotransformation, distribution, protein or red blood cell binding, transporter mediated disposition and urinary and/or biliary‐fecal ...
Vijay More, Kiran Deshpande, Chaitali Passey, Gaurav Bajaj, Jeff Barrett, Manish Gupta   +5 more
wiley   +1 more source

Effects of OAT3 siRNA on Mas receptor and peNOS expression in HK-2 cells.

, 2014
HK-2 cells were treated with or without OAT3 siRNA (siOAT3, 10 nM) (A). Mas receptor (B) and peNOS (C) protein expression was abolished by knocking down OAT3.
Chien-Te Lee (280488), Yelixiati Adelibieke (533238), Shinichi Saito (533237), Hwee-Yeong Ng (533235), Toshimitsu Niwa (533239), Fuyuhiko Nishijima (315403), Maimaiti Yisireyili (533236)   +6 more
core   +1 more source

OAT1 and OAT3: Targets of drug–drug interaction between entecavir and JBP485

European Journal of Pharmaceutical Sciences, 2013
Entecavir and JBP485 (a dipeptide) exhibit the antihepatitis activities and it is possible for the two drugs to be coadministered in the treatment of hepatitis. We aimed to elucidate whether entecavir was a substrate of OAT1, OAT3, OCT, and PEPT1 and to investigate the targets of drug-drug interactions between entecavir and JBP485.
Qinghan, Xu, Changyuan, Wang, Qiang, Meng, Qi, Liu, Huijun, Sun, Jinyong, Peng, Xiaochi, Ma, Taiichi, Kaku, Kexin, Liu   +8 more
openaire   +2 more sources

Interactions of organophosphate flame retardants with human drug transporters

Ecotoxicology and Environmental Safety, 2023
Organophosphate flame retardants (OPFRs) are environmental pollutants of increasing interest, widely distributed in the environment and exerting possible deleterious effects towards the human health. The present study investigates in vitro their possible
Valentin Tastet, Marc Le Vée, Marie Kerhoas, Anna Zerdoug, Elodie Jouan, Arnaud Bruyère, Olivier Fardel   +6 more
doaj   +1 more source

Pediatric Developmental Safety Assessment and New Approach Methodologies: US FDA/Triangle CERSI Workshop Report

Clinical Pharmacology &Therapeutics, Volume 120, Issue 5, Page 1240-1249, November 2026.
Pediatric developmental safety assessment presents distinct challenges in drug development. Children undergo dynamic changes in organ systems and drug disposition pathways during development, and drug‐related effects may be delayed or manifested differently than in adults.
Gilbert J. Burckart, Gelareh Abulwerdi, Christin L. Daniels, Calib Choi, Rebecca Racz, Jean‐Pierre Valentin, Kristin Ardlie, Nicholas Tatonetti, Susan Laffan, Marjory Moreau, Will Redfern, Lang Li, James J. Hickman, Rajanikanth Madabushi, Bhagwat Prasad, Lynne Yao, Paul B. Watkins   +16 more
wiley   +1 more source

Differences in the substrate binding regions of renal organic anion transporters 1 (OAT1) and 3 (OAT3)

, 2011
This study examined the selectivity of organic anion transporters OAT1 and OAT3 for structural congeners of the heavy metal chelator 2,3-dimercapto-1-propanesulfonic acid (DMPS).
Ryan M. Pelis, Stephen H. Wright, Theresa M. Wunz, Mark Morales, Bethzaida Astorga   +4 more
core   +1 more source

Practical Considerations for the Design, Conduct, and Reporting of Clinical Pharmacokinetic Drug–Drug Interaction Studies in Drug Development

The Journal of Clinical Pharmacology, Volume 66, Issue 11, November 2026.
Abstract Clinical pharmacokinetic drug–drug interaction (PK‐DDI) studies are frequently required in drug development when metabolizing enzymes and transporters determine pharmacokinetics. Drugs can be victims, perpetrators, or victims and perpetrators, of PK‐DDIs, so the clinical consequences of these interactions, particularly the risks of severe ...
Thomas M. Polasek, John O. Miners
wiley   +1 more source

Probenecid‐Boosted Tenofovir: A Physiologically‐Based Pharmacokinetic Model‐Informed Strategy for On‐Demand HIV Preexposure Prophylaxis

CPT: Pharmacometrics & Systems Pharmacology, 2020
Multiple doses of tenofovir disoproxil fumarate (TDF) together with emtricitabine is effective for HIV preexposure prophylaxis (PrEP). TDF is converted to tenofovir (TFV) in circulation, which is subsequently cleared via tubular secretion by organic ion ...
Stephanie N. Liu, Zeruesenay Desta, Brandon T. Gufford   +2 more
doaj   +1 more source

Drug–Drug Interactions of Cenobamate With Medications: Dose‐Dependent Induction/Inhibition and Clinical Implications

CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 11, November 2026.
ABSTRACT Cenobamate causes dose‐dependent cytochrome P450 (CYP)2B6 and CYP3A4 induction and CYP2C19 inhibition, raising concern over multi‐pathway drug–drug interactions (DDIs) in patients with epilepsy treated with cardiovascular co‐medications. We developed a physiologically based pharmacokinetic (PBPK) model for cenobamate and verified it using ...
Hiroyuki Ichida, Takaharu Nakao, Takanori Mori, Reina Makino, Marika Nakagawa, Kazuhiro Yoneda, Yoshiyuki Yamaura, Masanori Kuribayashi   +7 more
wiley   +1 more source

Organic anion transporter 3 (Oat3/Slc22a8) knockout mice exhibit altered clearance and distribution of penicillin G

, 2007
The interaction of renal basolateral organic anion transporter 3 (Oat3) with commonly used pharmacotherapeutics (e.g., NSAIDs, β-lactams, and methotrexate) has been studied extensively in vitro.
VanWert, Adam L., Rachel M. Bailey, Douglas H. Sweet, Bailey, Rachel M., Sweet, Douglas H., Adam L. VanWert   +5 more
core   +1 more source